Identification and evaluation of novel drug combinations of Aurora kinase inhibitor CCT137690 for enhanced efficacy in oral cancer cells
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Identification and evaluation of novel drug combinations of Aurora kinase inhibitor CCT137690 for enhanced efficacy in oral cancer cells
Authors
Keywords
-
Journal
CELL CYCLE
Volume -, Issue -, Pages 1-12
Publisher
Informa UK Limited
Online
2019-07-19
DOI
10.1080/15384101.2019.1643658
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The 4717C > G polymorphism in periplakin modulates sensitivity to EGFR inhibitors
- (2019) Hui Mei Lee et al. Scientific Reports
- CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
- (2018) Jeffrey E. Lancet et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification and characterization of SSE15206, a microtubule depolymerizing agent that overcomes multidrug resistance
- (2018) Safia Manzoor et al. Scientific Reports
- Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer
- (2018) Khyati N. Shah et al. NATURE MEDICINE
- Recent advances in nanoparticle-mediated drug delivery
- (2017) Bipul Kumar et al. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
- Micellear Gold Nanoparticles as Delivery Vehicles for Dual Tyrosine Kinase Inhibitor ZD6474 for Metastatic Breast Cancer Treatment
- (2017) Siddik Sarkar et al. LANGMUIR
- Aurora B Expression as a Prognostic Indicator and Possibile Therapeutic Target in Oral Squamous Cell Carcinoma
- (2017) G. Pannone et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo
- (2016) Susan Ashton et al. Science Translational Medicine
- Genetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapies
- (2016) Muhammad Zaki Hidayatullah Fadlullah et al. Oncotarget
- 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained
- (2016) Michele Zanoni et al. Scientific Reports
- Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study
- (2015) Bohuslav Melichar et al. LANCET ONCOLOGY
- Aurora Kinase Inhibitors: Current Status and Outlook
- (2015) Vassilios Bavetsias et al. Frontiers in Oncology
- Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck
- (2015) Alexander Hoellein et al. Oncotarget
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery
- (2014) Vladimir P. Torchilin NATURE REVIEWS DRUG DISCOVERY
- Histological and molecular aspects of oral squamous cell carcinoma (Review)
- (2014) CÉSAR RIVERA et al. Oncology Letters
- Nanoparticles for Combination Drug Therapy
- (2013) Liang Ma et al. ACS Nano
- Aurora kinases in head and neck cancer
- (2013) Ranee Mehra et al. LANCET ONCOLOGY
- Targeting Aurora kinase A suppresses the growth of human oral squamous cell carcinoma cells in vitro and in vivo
- (2013) Hiroshi Tanaka et al. ORAL ONCOLOGY
- Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
- (2012) A S Moore et al. LEUKEMIA
- Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery
- (2012) S. Karve et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo
- (2011) A. Faisal et al. MOLECULAR CANCER THERAPEUTICS
- Imidazo[4,5-b]pyridine Derivatives As Inhibitors of Aurora Kinases: Lead Optimization Studies toward the Identification of an Orally Bioavailable Preclinical Development Candidate
- (2010) Vassilios Bavetsias et al. JOURNAL OF MEDICINAL CHEMISTRY
- Oral cavity cancer in developed and in developing countries: Population-based incidence
- (2009) Marianna de Camargo Cancela et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Nanoparticles engineered from lecithin-in-water emulsions as a potential delivery system for docetaxel
- (2009) Nijaporn Yanasarn et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells
- (2009) P. Kaestner et al. MOLECULAR CANCER THERAPEUTICS
- Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma
- (2008) Abhijit Mazumdar et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Recent Advances in Head and Neck Cancer
- (2008) Robert I. Haddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aurora kinase small molecule inhibitor destroys mitotic spindle, suppresses cell growth, and induces apoptosis in oral squamous cancer cells
- (2007) Caobing Pan et al. ORAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now